Journals / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 8

Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study

Pages
685–693
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall survival was not different between the 2 groups (HCC-NCL: 19.4 ± 9.8 months vs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: A small proportion of all hepatocellular carcinomas (HCCs) arise in a non-cirrhotic liver (NCL).
📊
Key Findings & Data:Methods: We retrospectively analyzed the database of patients with HCC at a tertiary center during a 10-year period (2009-2019).
💡
Conclusion & Impact:The overall survival was not different between the 2 groups (HCC-NCL: 19.4 ± 9.8 months vs.
🔬Design:Research Article
📍Scope:2009-2019 Verileri
⚙️Variables:Domain Parameters

Özet

Background: A small proportion of all hepatocellular carcinomas (HCCs) arise in a non-cirrhotic liver (NCL). However, our knowledge about the HCCs developing in a NCL is scarce. This study was undertaken to investigate the characteristics and survival course of this patient group. Methods: We retrospectively analyzed the database of patients with HCC at a tertiary center during a 10-year period (2009-2019). All demographic, clinical, laboratory, and tumoral features with survival outcomes were compared between the HCC-CL and HCC-NCL groups. Results: Out of 384 HCC cases, 11.2% (n = 43) had no cirrhosis. The dominant etiology in the HCC-NCL group was hepatitis B virus (n = 26, 60.5%), followed by non-alcoholic fatty liver disease (n = 10, 23.2%), and hepatitis C virus (n = 7, 16.3%). The maximum tumor diameter was approximately 2 times larger in the HCC-NCL group (HCC-NCL: 90 mm vs. HCC-CL: 46.5 mm, P < .001). The proportion of patients with vascular (HCC-NCL: 27.9% vs. HCC-CL: 8.6%, P < .001) and extrahepatic invasion (HCC-NCL: 14% vs. HCC-CL: 3%, P = .001) were prominently higher in the HCC-NCL group. Patients with HCC-NCL were less often detected in early-curable stages (BCLC 0-A) than those in the HCC-CL group (HCC-NCL: 16.3% vs. HCC-CL: 34.9%, P = .004). The overall survival was not different between the 2 groups (HCC-NCL: 19.4 ± 9.8 months vs. HCC-CL: 17.5 ± 2.3 months, P = .581). Conclusion: HCC in NCL is diagnosed at more advanced tumoral stages with larger tumor size and more often with vascular and extrahepatic spread. Despite the preserved liver functions, the overall survival is not prolonged in HCCs without cirrhosis, due to the late recognition.

🔖

Cite This Article

DEMİRTAŞ, C. Ö., TOLU, T., KEKLİKKİRAN, C., ÖZDOĞAN, O. C., GÜNDÜZ, F. (2021). Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 8, 685–693. https://ajindex.com/articles/408640

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019
  2. 144(8):1941-1953. [CrossRef] 2. Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int. 2019
  3. 39(6):1098-1108. [CrossRef ] 3. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci. 2015
  4. 60(10):3142-3148. [CrossRef] 4. Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol. 2010
  5. 16(32):4061-4065. [CrossRef] 5. Albeldawi M, Soliman M, Lopez R, Zein NN. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients. Dig Dis Sci. 2012
  6. 57(12):3265-3270. [CrossRef] 6. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010
  7. 12(8):509-522. [CrossRef] 7. Chu YJ, Yang HI, Wu HC, et al. Aflatoxin b1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer. 2017
  8. 141(4):711-720. [CrossRef] 8. Hiatt T, Trotter JF, Kam I. Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci. 2007
  9. 334(3):228-230. [CrossRef] 9. Topic A, Ljujic M, Radojkovic D. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon. 2012
  10. 12(10 HCC):e7042. [CrossRef] 10. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer. 2017
  11. 48(3):238-240. [CrossRef] 11. Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol. 2019
  12. 31(7):743-748. [CrossRef] 12. Akkiz H, Carr BI, Yalçın K KK, et al. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology. 2018
  13. 94(2):116-124. [CrossRef] 13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018
  14. 69(1):182-236. [CrossRef] 14. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated With nonalcoholic fatty